Renal Cancer - Results from #1620

Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma. February 21, 2022

Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. February 18, 2022

Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial. February 18, 2022

Renal Cell Carcinoma Surgical Treatment Disparities in American Indian/Alaska Natives and Hispanic Americans in Arizona. February 17, 2022

The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics-Definition, Current Advances, and Future Directions. February 17, 2022

Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts? February 17, 2022

Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. February 16, 2022

Systematic Review With Meta-Analysis: Diagnostic, Prognostic and Clinicopathological Significance of CircRNA Expression in Renal Cancer. February 16, 2022

Perspectives on the Role of Biopsy for Management of T1 Renal Masses: Survey Results from Two Regional Quality Improvement Collaboratives. February 15, 2022

Partial vs. radical nephrectomy in non-metastatic pT3a kidney cancer patients: a population-based study. February 15, 2022

Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point. February 14, 2022

C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery. February 14, 2022

Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy. February 11, 2022

Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis. February 11, 2022

PAQR5 Expression Is Suppressed by TGFβ1 and Associated With a Poor Survival Outcome in Renal Clear Cell Carcinoma. February 10, 2022

Prognostic Significance of Modified Advanced Lung Cancer Inflammation Index in Patients With Renal Cell Carcinoma Undergoing Laparoscopic Nephrectomy: A Multi-Institutional, Propensity Score Matching Cohort Study. February 9, 2022

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. February 9, 2022

Soluble PD-L1 as an early marker of progressive disease on nivolumab. February 9, 2022

Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC). February 8, 2022

Update on the treatment of metastatic renal cell carcinoma. February 8, 2022

Page 82 of 456